FI3006038T3 - Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn - Google Patents
Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn Download PDFInfo
- Publication number
- FI3006038T3 FI3006038T3 FIEP15195726.3T FI15195726T FI3006038T3 FI 3006038 T3 FI3006038 T3 FI 3006038T3 FI 15195726 T FI15195726 T FI 15195726T FI 3006038 T3 FI3006038 T3 FI 3006038T3
- Authority
- FI
- Finland
- Prior art keywords
- bacterial infection
- prophylaxis
- staphylococcus aureus
- prevention
- pharmaceutical composition
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title claims 20
- 208000022362 bacterial infectious disease Diseases 0.000 title claims 20
- 229960001607 oritavancin Drugs 0.000 title claims 5
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 title claims 5
- 108010006945 oritavancin Proteins 0.000 title claims 5
- 238000011321 prophylaxis Methods 0.000 claims 15
- 241000191967 Staphylococcus aureus Species 0.000 claims 14
- 241000894006 Bacteria Species 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 10
- 108010059993 Vancomycin Proteins 0.000 claims 7
- 229960003165 vancomycin Drugs 0.000 claims 7
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 7
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 7
- 241000194032 Enterococcus faecalis Species 0.000 claims 6
- 229940032049 enterococcus faecalis Drugs 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 4
- 241000193985 Streptococcus agalactiae Species 0.000 claims 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims 4
- 229960003085 meticillin Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940030998 streptococcus agalactiae Drugs 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9331408P | 2008-08-30 | 2008-08-30 | |
| US9349708P | 2008-09-02 | 2008-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3006038T3 true FI3006038T3 (fi) | 2024-08-12 |
Family
ID=41722337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15195726.3T FI3006038T3 (fi) | 2008-08-30 | 2009-08-29 | Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8420592B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3006038B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5782615B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102215858A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009285564B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2736860C (cg-RX-API-DMAC7.html) |
| DK (2) | DK3006038T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA020490B1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2994966T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3006038T3 (cg-RX-API-DMAC7.html) |
| HU (3) | HUE068423T2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011002249A (cg-RX-API-DMAC7.html) |
| NL (1) | NL300834I2 (cg-RX-API-DMAC7.html) |
| NO (1) | NO2016019I2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ591525A (cg-RX-API-DMAC7.html) |
| PL (2) | PL3006038T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3006038T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010025438A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2424559T3 (pl) * | 2009-04-28 | 2024-07-29 | Melinta Therapeutics, Llc | Sposoby leczenia zakażeń bakteryjnych z zastosowaniem orytawancyny |
| WO2014031681A1 (en) * | 2012-08-20 | 2014-02-27 | The University Of Chicago | Inhibiting gram positive bacteria |
| WO2014176068A2 (en) * | 2013-04-22 | 2014-10-30 | The Medicines Company | Treatment and prevention of bacterial skin infections using oritavancin |
| US20160206688A1 (en) * | 2013-08-26 | 2016-07-21 | The Medicines Company | Methods for treating bacteremia and osteomyelitis using oritavancin |
| WO2015031579A2 (en) * | 2013-08-28 | 2015-03-05 | The Medicines Company | Methods for treating bacterial infections using oritavancin and polymyxins |
| US20170119793A1 (en) * | 2014-06-12 | 2017-05-04 | Cem-102 Pharmaceuticals, Inc. | Compositions and methods for treating bone and joint infections |
| HUE070928T2 (hu) | 2014-07-17 | 2025-07-28 | Melinta Therapeutics Llc | Nagy tisztaságú oritavancin és eljárás annak elõállítására |
| BR112018016715A2 (pt) * | 2016-02-18 | 2019-02-19 | Melinta Therapeutics, Inc. | ?formulações de oritavancina? |
| US20200171124A1 (en) * | 2016-04-15 | 2020-06-04 | Lupin Limited | Topical compositions for ophthalmic and otic use |
| CN108409837B (zh) * | 2018-03-06 | 2021-09-24 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| US5994297A (en) * | 1997-08-22 | 1999-11-30 | Eli Lilly And Company | Therapy for Staphylococcus aureus |
| IL145582A0 (en) * | 1999-05-03 | 2002-06-30 | Lilly Co Eli | Monthly doses for treatment of streptococcus pneumoniae infections |
| ES2316445T3 (es) | 2000-05-02 | 2009-04-16 | Theravance, Inc. | Composicion que contiene una ciclodextrina y un antibiotico glicopeptidico. |
| US20030176327A1 (en) * | 2001-10-25 | 2003-09-18 | Cassell Gail Houston | Antibiotics for treating biohazardous bacterial agents |
| WO2003102134A2 (en) * | 2002-05-28 | 2003-12-11 | Becton, Dickinson And Company | Pancreatic acinar cells into insulin producing cells |
| WO2004017925A2 (en) * | 2002-08-23 | 2004-03-04 | Genome Therapeutics Corporation | Methods and reagents for preventing bacteremias |
| US20040127403A1 (en) * | 2002-09-06 | 2004-07-01 | Francesco Parenti | Methods for treating and preventing Gram-positive bacteremias |
| US20070249577A1 (en) * | 2005-05-10 | 2007-10-25 | Hopkins Scott J | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures |
| WO2008097364A2 (en) * | 2006-09-25 | 2008-08-14 | Targanta Therapeutics Corp. | Use of oritavancin for prevention and treatment of anthrax |
-
2009
- 2009-08-29 PL PL15195726.3T patent/PL3006038T3/pl unknown
- 2009-08-29 CA CA2736860A patent/CA2736860C/en active Active
- 2009-08-29 DK DK15195726.3T patent/DK3006038T3/da active
- 2009-08-29 FI FIEP15195726.3T patent/FI3006038T3/fi active
- 2009-08-29 EP EP15195726.3A patent/EP3006038B1/en active Active
- 2009-08-29 EA EA201100413A patent/EA020490B1/ru unknown
- 2009-08-29 US US13/060,811 patent/US8420592B2/en active Active
- 2009-08-29 HU HUE15195726A patent/HUE068423T2/hu unknown
- 2009-08-29 AU AU2009285564A patent/AU2009285564B2/en active Active
- 2009-08-29 PT PT151957263T patent/PT3006038T/pt unknown
- 2009-08-29 CN CN2009801439475A patent/CN102215858A/zh active Pending
- 2009-08-29 EP EP09810708.9A patent/EP2337575B1/en not_active Revoked
- 2009-08-29 WO PCT/US2009/055466 patent/WO2010025438A2/en not_active Ceased
- 2009-08-29 ES ES15195726T patent/ES2994966T3/es active Active
- 2009-08-29 MX MX2011002249A patent/MX2011002249A/es active IP Right Grant
- 2009-08-29 CN CN201610900690.5A patent/CN106620649A/zh active Pending
- 2009-08-29 NZ NZ591525A patent/NZ591525A/en unknown
- 2009-08-29 ES ES09810708T patent/ES2570401T3/es active Active
- 2009-08-29 PL PL09810708.9T patent/PL2337575T3/pl unknown
- 2009-08-29 EP EP24186111.1A patent/EP4464375A3/en active Pending
- 2009-08-29 DK DK09810708.9T patent/DK2337575T3/en active
- 2009-08-29 HU HUE09810708A patent/HUE027373T2/hu unknown
- 2009-08-29 JP JP2011525264A patent/JP5782615B2/ja active Active
-
2016
- 2016-10-06 HU HUS1600039C patent/HUS1600039I1/hu unknown
- 2016-10-11 NL NL300834C patent/NL300834I2/nl unknown
- 2016-10-11 NO NO2016019C patent/NO2016019I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3006038T3 (fi) | Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn | |
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| ES2856831T3 (es) | Una composición que comprende un antibiótico no peptídico y cisteamina | |
| JP2012501349A5 (cg-RX-API-DMAC7.html) | ||
| Blanchette et al. | Current therapies in treatment and prevention of fracture wound biofilms: why a multifaceted approach is essential for resolving persistent infections | |
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| EA200800798A1 (ru) | Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха | |
| JP2004339238A5 (cg-RX-API-DMAC7.html) | ||
| JP7041166B2 (ja) | トリアリールポリアミンを含む組成物および方法 | |
| RU2014134720A (ru) | Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения | |
| Jugun et al. | The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| CA2617133A1 (en) | Compositions and methods for treating bacteria | |
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| Silvestri et al. | In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection | |
| AU2019312592A1 (en) | Bismuth-thiol compositions and methods for treating wounds | |
| CA3143793C (en) | Biofilm disruption | |
| CA3139942A1 (en) | Medicament and use thereof for treating bacterial infections involving biofilm | |
| WO2020081247A1 (en) | Potentiated antibiotic compositions and methods of use for treating bacterial infections and biofilms | |
| MX336278B (es) | Composiciones y metodos para la prevencion y el tratamiento de heridas. | |
| CA2566687A1 (en) | The use of tiacumicin b in the treatment of antibiotic resistant staphylococcus or vancomycin-resistant enterococci infections | |
| EP2529737A1 (en) | Antibacterial combination therapy | |
| EP1689405B1 (en) | Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance | |
| Naselli et al. | Granulated sugar for adjuvant treatment of surgical wound infection due to multi-drug-resistant pathogens in a child with sarcoma: a case report and literature review | |
| Deabate et al. | Modern antibiotic treatment of chronic long bone infections in adults-theory, evidence and practice |